Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414488 | 0.78 | MAPT (0.50) | MAPTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL1414396 | 0.75 | MAPT (0.39) | MAPTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL1414573 | 0.71 | NOD2 (0.33) | MAPTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1414395 | 0.67 | GFER (0.53) | MAPTALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL941784 | 0.65 | MAPT (0.43) | MAPTALDH1A1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL939996 | 0.65 | KIT (0.51) | MAPTNPC1 | |
| SCHEMBL18737412 | 0.64 | MAPT (0.79) | MAPTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL6479650 | 0.64 | MEN1 (0.54) | ALDH1A1LMNASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5964942 | 0.64 | MAPT (0.56) | MAPTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL940590 | 0.64 | MAPT (0.44) | MAPTALDH1A1NPSR1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338411-B2 | Compounds | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-2167470-B1 | TRIAZOLO [1, 5-A]QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20100216786-A1 | NEW COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| EP-2167470-A1 | TRIAZOLO [1, 5-A]QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008149168-A1 | TRIAZOLO [1, 5-A] QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216786-A1 | NEW COMPOUNDS | ADORA3, ADORA2A, ADORA1 | MAPT 3856/4885ALDH1A1 1126/4885LMNA 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.